Nurix Therapeutics, Inc. (NRIX) shareholders
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
117M of 109M shares
Institutional holders
211
47 new, 28 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 48 sales
Net sold $5.84M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jeremy C. Green Joint filing with Redmile Group, LLC (9.90%), RedCo II Offshore SPV LLC (5.60%) | 10,696,314 | 9.90% | 13G (passive) amendment | Apr 20, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (11.50%) | 8,787,537 | 11.50% | 13G (passive) amendment | Sep 30, 2025 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (8.10%) | 8,782,256 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| Ryan Wilder Joint filing with Vestal Point Capital, LP (7.80%) | 8,050,000 | 7.80% | 13G (passive) amendment | Jun 30, 2026 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (7.45%), David Kroin (7.45%) | 7,736,455 | 7.45% | 13G (passive) amendment | Jun 30, 2026 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (7.20%), Julian C. Baker (7.20%) and 1 more | 7,527,996 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
| Rubric Capital Management LP Joint filing with David Rosen (6.96%) | 7,227,778 | 6.96% | 13G (passive) | Jun 30, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (6.17%), David Kroin (6.17%) | 6,345,244 | 6.17% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 6,284,116 | 8.20% | 13G (passive) amendment | Mar 31, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (5.30%), Joseph Edelman (5.30%) | 5,536,629 | 5.30% | 13G (passive) | Sep 16, 2026 |
| David Kroin Joint filing with Deep Track Capital, LP (7.21%), Deep Track Biotechnology Master Fund, Ltd. (7.21%) | 5,500,000 | 7.21% | 13G (passive) amendment | Mar 31, 2025 |
| T. Rowe Price Associates, Inc. | 5,436,587 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 5,202,025 | 5.03% | 13G (passive) | Jun 30, 2026 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (5.10%) | 3,850,000 | 5.10% | 13G (passive) | Feb 7, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NRIX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,770,349 | 8.03% | $212.77M | −155,293 | 0.00% |
| Vestal Point Capital, LP | 8,050,000 | 7.37% | $195.29M | +1,550,000 | 4.56% |
| Deep Track Capital, LP | 7,736,455 | 7.08% | $187.69M | +1,391,211 | 2.73% |
| Rubric Capital Management LP | 7,227,778 | 6.62% | $175.35M | +4,753,893 | 1.61% |
| FMR LLC | 5,485,215 | 5.02% | $133.07M | −56,056 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 5,436,587 | 4.98% | $131.89M | +2,146,354 | 0.01% |
| Morgan Stanley | 4,762,484 | 4.36% | $115.54M | −169,515 | 0.01% |
| State Street Corp | 4,677,244 | 4.28% | $113.47M | −463,951 | 0.00% |
| Baker Bros. Advisors LP | 4,658,556 | 4.26% | $113.02M | – | 0.57% |
| Vanguard Capital Management LLC | 4,495,529 | 4.11% | $109.06M | +68,417 | 0.00% |
| Perceptive Advisors LLC | 4,320,422 | 3.95% | $104.81M | +609,545 | 1.57% |
| Redmile Group, LLC | 4,073,787 | 3.73% | $98.83M | −3,659,021 | 6.64% |
| General Atlantic, L.P. | 3,032,185 | 2.78% | $73.56M | −1,069,680 | 2.53% |
| Geode Capital Management, LLC | 2,537,291 | 2.32% | $61.57M | +17,062 | 0.00% |
| Pictet Asset Management Holding SA | 2,351,232 | 2.15% | $57.04M | −374,906 | 0.05% |
| ARK Investment Management LLC | 1,793,196 | 1.64% | $43.50M | +72,061 | 0.28% |
| Capital World Investors | 1,787,916 | 1.64% | $43.37M | +894,589 | 0.01% |
| Trails Edge Capital Partners, LP | 1,573,220 | 1.44% | $38.17M | −170,000 | 6.06% |
| Vanguard Portfolio Management LLC | 1,482,861 | 1.36% | $35.97M | +380,595 | 0.00% |
| Citadel Advisors LLC | 1,477,019 | 1.35% | $35.83M | +133,319 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 211 | 117M | 100.0% | 47 / 67 | 63 / 28 | 18M | 18M |
| Q1 2026 | 196 | 117M | 100.0% | 44 / 67 | 43 / 27 | 20M | 10M |
| Q4 2025 | 182 | 114M | 100.0% | 39 / 93 | 29 / 28 | 43M | 14M |
| Q3 2025 | 173 | 85M | 77.6% | 34 / 50 | 59 / 24 | 9M | 13M |
| Q2 2025 | 163 | 88M | 80.9% | 23 / 68 | 44 / 30 | 13M | 9M |
| Q1 2025 | 170 | 85M | 77.5% | 29 / 66 | 51 / 32 | 11M | 7M |
| Q4 2024 | 175 | 81M | 74.2% | 36 / 66 | 47 / 31 | 21M | 8M |
| Q3 2024 | 172 | 68M | 62.2% | 29 / 65 | 58 / 30 | 16M | 6M |
| Q2 2024 | 174 | 65M | 59.5% | 53 / 62 | 45 / 17 | 21M | 10M |
| Q1 2024 | 139 | 54M | 49.6% | 28 / 42 | 44 / 17 | 10M | 5M |
| Q4 2023 | 130 | 49M | 45.1% | 25 / 46 | 37 / 23 | 11M | 7M |
| Q3 2023 | 128 | 45M | 41.0% | 13 / 41 | 51 / 10 | 4M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
199 funds held NRIX in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NRIX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,273,943 | 3.00% | $79.43M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,506,930 | 2.29% | $60.82M | 0.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,459,381 | 2.25% | $59.66M | 0.56% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,739,335 | 1.59% | $42.20M | 0.04% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 1,682,054 | 1.54% | $39.04M | 2.51% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,297,893 | 1.19% | $31.49M | 1.76% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,186,512 | 1.09% | $28.78M | 0.24% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,114,472 | 1.02% | $27.04M | 0.03% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,097,649 | 1.00% | $26.63M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,047,808 | 0.96% | $24.32M | 0.07% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 948,302 | 0.87% | $22.01M | 0.25% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 942,854 | 0.86% | $22.87M | 0.23% | Jun 30, 2026 |
| iShares Biotechnology ETF | 695,275 | 0.64% | $16.87M | 0.19% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 681,706 | 0.62% | $16.54M | 0.11% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 646,065 | 0.59% | $11.47M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Arthur T. Sands | President, CEO, Director | 608,333 | 0.56% | Feb 10, 2026 |
| Houte Hans van | Chief Financial Officer | 42,745 | 0.04% | Nov 4, 2026 |
| Christine Ring | Chief Legal Officer | 4,406 | 0.00% | Nov 4, 2026 |
| Gwenn Hansen | Chief Scientific Officer | 123,452 | 0.11% | Nov 2, 2026 |
| Julia P. Gregory | Director | 10,750 | 0.01% | Oct 14, 2026 |
| Edward C. Saltzman | Director | – | – | May 15, 2026 |
| Judith A. Reinsdorf | Director | – | – | May 15, 2026 |
| Roy D. Baynes | Director | – | – | May 15, 2026 |
| Paul M. Silva | Director | – | – | May 15, 2026 |
| Anil Kapur | Director | – | – | May 15, 2026 |
| David L. Lacey | Director | 33,333 | 0.03% | May 15, 2026 |
| Roger D. Dansey | Director | – | – | May 15, 2026 |
| Lori Anne Kunkel | Director | 0 | – | May 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Houte Hans van Chief Financial Officer | Nov 4, 2026 | Sale(10b5-1 plan) | −1,469 | $16.20 | $23.80K | 42,745 |
| Houte Hans van Chief Financial Officer | Nov 4, 2026 | Sale(10b5-1 plan) | −3,300 | $15.38 | $50.76K | 44,214 |
| Christine Ring Chief Legal Officer | Nov 3, 2026 | Sale(10b5-1 plan) | −6,113 | $25.83 | $157.92K | 4,406 |
| Christine Ring Chief Legal Officer | Nov 2, 2026 | Sale(10b5-1 plan) | −1,075 | $26.76 | $28.77K | 10,519 |
| Christine Ring Chief Legal Officer | Nov 2, 2026 | Sale(10b5-1 plan) | −9,527 | $25.74 | $245.22K | 11,594 |
| Christine Ring Chief Legal Officer | Nov 2, 2026 | Option exercise | +5,786 | $8.72 | $50.45K | 21,121 |
| Gwenn Hansen Chief Scientific Officer | Nov 2, 2026 | Sale(10b5-1 plan) | −1,452 | $26.80 | $38.91K | 123,452 |
| Gwenn Hansen Chief Scientific Officer | Nov 2, 2026 | Option exercise | +1,452 | $1.86 | $2.70K | 124,904 |
| Houte Hans van Chief Financial Officer | Oct 30, 2026 | Sale | −2,834 | $26.28 | $74.47K | 47,514 |
| Houte Hans van Chief Financial Officer | Oct 30, 2026 | Option exercise | +3,573 | – | – | 50,348 |
| Houte Hans van Chief Financial Officer | Oct 30, 2026 | Option exercise | +2,859 | – | – | 46,775 |
| Houte Hans van Chief Financial Officer | Oct 30, 2026 | Option exercise | +3,750 | – | – | 43,916 |
| Christine Ring Chief Legal Officer | Oct 30, 2026 | Sale | −3,957 | $26.28 | $103.99K | 15,335 |
| Christine Ring Chief Legal Officer | Oct 30, 2026 | Option exercise | +3,573 | – | – | 19,292 |
| Christine Ring Chief Legal Officer | Oct 30, 2026 | Option exercise | +2,859 | – | – | 15,719 |
| Christine Ring Chief Legal Officer | Oct 30, 2026 | Option exercise | +3,750 | – | – | 12,860 |
| Gwenn Hansen Chief Scientific Officer | Oct 30, 2026 | Sale(10b5-1 plan) | −3,957 | $26.28 | $103.99K | 123,452 |
| Gwenn Hansen Chief Scientific Officer | Oct 30, 2026 | Option exercise | +3,573 | – | – | 127,409 |
| Gwenn Hansen Chief Scientific Officer | Oct 30, 2026 | Option exercise | +2,859 | – | – | 123,836 |
| Gwenn Hansen Chief Scientific Officer | Oct 30, 2026 | Option exercise | +3,750 | – | – | 120,977 |
| Gwenn Hansen Chief Scientific Officer | Oct 15, 2026 | Sale(10b5-1 plan) | −1,452 | $25.00 | $36.30K | 117,227 |
| Gwenn Hansen Chief Scientific Officer | Oct 15, 2026 | Option exercise | +1,452 | $1.86 | $2.70K | 118,679 |
| Julia P. Gregory Director | Oct 14, 2026 | Sale | −22,583 | $23.40 | $528.53K | 10,750 |
| Julia P. Gregory Director | Oct 14, 2026 | Option exercise | +22,583 | $1.86 | $42.00K | 33,333 |
| Christine Ring Chief Legal Officer | Oct 2, 2026 | Sale(10b5-1 plan) | −5,786 | $23.19 | $134.15K | 9,110 |
| Christine Ring Chief Legal Officer | Oct 2, 2026 | Option exercise | +5,786 | $8.72 | $50.45K | 14,896 |
| Christine Ring Chief Legal Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −5,387 | $25.69 | $138.39K | 9,510 |
| Christine Ring Chief Legal Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −400 | $26.64 | $10.66K | 9,110 |
| Christine Ring Chief Legal Officer | Sep 2, 2026 | Option exercise | +5,787 | $8.72 | $50.46K | 14,897 |
| Gwenn Hansen Chief Scientific Officer | Sep 1, 2026 | Option exercise | +1,452 | $1.86 | $2.70K | 118,679 |
| Gwenn Hansen Chief Scientific Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −1,452 | $25.47 | $36.98K | 117,227 |
| Gwenn Hansen Chief Scientific Officer | Aug 5, 2026 | Option exercise | +4,356 | $1.86 | $8.10K | 121,583 |
| Gwenn Hansen Chief Scientific Officer | Aug 5, 2026 | Sale(10b5-1 plan) | −4,356 | $25.00 | $108.90K | 117,227 |
| Gwenn Hansen Chief Scientific Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −1,500 | $23.87 | $35.81K | 119,838 |
| Gwenn Hansen Chief Scientific Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −2,611 | $24.64 | $64.34K | 117,227 |
| Houte Hans van Chief Financial Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −2,967 | $24.65 | $73.14K | 40,166 |
| Houte Hans van Chief Financial Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −1,794 | $23.89 | $42.86K | 43,133 |
| Christine Ring Chief Legal Officer | Aug 3, 2026 | Option exercise | +5,787 | $8.72 | $50.46K | 25,699 |
| Christine Ring Chief Legal Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −16,589 | $23.05 | $382.38K | 9,110 |
| Christine Ring Chief Legal Officer | Jul 30, 2026 | Sale | −3,847 | $23.38 | $89.94K | 19,912 |
| Christine Ring Chief Legal Officer | Jul 30, 2026 | Option exercise | +3,750 | – | – | 17,329 |
| Christine Ring Chief Legal Officer | Jul 30, 2026 | Option exercise | +2,858 | – | – | 20,187 |
| Christine Ring Chief Legal Officer | Jul 30, 2026 | Option exercise | +3,572 | – | – | 23,759 |
| Houte Hans van Chief Financial Officer | Jul 30, 2026 | Option exercise | +2,858 | – | – | 44,200 |
| Houte Hans van Chief Financial Officer | Jul 30, 2026 | Option exercise | +3,572 | – | – | 47,772 |
| Houte Hans van Chief Financial Officer | Jul 30, 2026 | Sale | −2,845 | $23.38 | $66.52K | 44,927 |
| Houte Hans van Chief Financial Officer | Jul 30, 2026 | Option exercise | +3,750 | – | – | 41,342 |
| Gwenn Hansen Chief Scientific Officer | Jul 30, 2026 | Option exercise | +3,750 | – | – | 118,755 |
| Gwenn Hansen Chief Scientific Officer | Jul 30, 2026 | Option exercise | +2,858 | – | – | 121,613 |
| Gwenn Hansen Chief Scientific Officer | Jul 30, 2026 | Sale | −3,847 | $23.38 | $89.94K | 121,338 |
| Gwenn Hansen Chief Scientific Officer | Jul 30, 2026 | Option exercise | +3,572 | – | – | 125,185 |
| Christine Ring Chief Legal Officer | Jul 2, 2026 | Option exercise | +5,221 | $1.86 | $9.71K | 18,800 |
| Christine Ring Chief Legal Officer | Jul 2, 2026 | Option exercise | +5,787 | $8.72 | $50.46K | 24,587 |
| Christine Ring Chief Legal Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −11,008 | $23.56 | $259.35K | 13,579 |
| Gwenn Hansen Chief Scientific Officer | Jun 25, 2026 | Sale(10b5-1 plan) | −5,394 | $20.00 | $107.88K | 115,005 |
| Christine Ring Chief Legal Officer | Jun 25, 2026 | Option exercise | +13,333 | $7.26 | $96.80K | 26,912 |
| Christine Ring Chief Legal Officer | Jun 25, 2026 | Option exercise | +15,602 | $8.72 | $136.05K | 42,514 |
| Christine Ring Chief Legal Officer | Jun 25, 2026 | Sale(10b5-1 plan) | −28,935 | $20.06 | $580.44K | 13,579 |
| Christine Ring Chief Legal Officer | Jun 2, 2026 | Option exercise | +3,422 | $1.86 | $6.36K | 21,727 |
| Christine Ring Chief Legal Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −8,148 | $16.60 | $135.26K | 13,579 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
17.90%
19M shares short
Days to cover
7.2
At 3M shares a day
Change since last report
-8.1%
From 21M shares
Short volume, 20 days
31.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nurix Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 180 shares on Aug 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Johannes Van Houte Officer | Nov 4, 2026 | 4,769 | $123.14K | Nov 4, 2026 | Restricted Stock Units |
| Christine Ring Officer | Nov 3, 2026 | 6,113 | $157.10K | Nov 3, 2026 | Restricted Stock Units |
| Christine Ring Officer | Nov 2, 2026 | 10,602 | $284.13K | Nov 2, 2026 | Exercise of Stock Options |
| Julia P. Gregory Director | Oct 14, 2026 | 22,583 | $528.53K | Oct 14, 2026 | Stock Option Exercise |
| Christine Ring Officer | Oct 2, 2026 | 5,786 | $135.05K | Oct 2, 2026 | Exercise of Stock Options |
| Christine Ring Officer | Sep 2, 2026 | 5,787 | $150.69K | Sep 2, 2026 | Exercise of Stock Options |
| Gwenn Hansen Officer | Aug 5, 2026 | 8,712 | $215.10K | Aug 5, 2026 | Exercise of Stock Options |
| Johannes Van Houte Officer | Aug 4, 2026 | 4,761 | $110.55K | Aug 4, 2026 | Restricted Stock Units |
| Gwenn Hansen Officer | Aug 4, 2026 | 4,111 | $95.46K | Aug 4, 2026 | Restricted Stock Units |
| Christine Ring Officer | Aug 3, 2026 | 16,589 | $385.03K | Aug 3, 2026 | Exercise of Stock Options |
| Christine Ring Officer | Jul 2, 2026 | 11,008 | $263.20K | Jul 2, 2026 | Exercise of Stock Options |
| Christine Ring Officer | Jun 25, 2026 | 28,935 | $558.45K | Jun 25, 2026 | Exercise of Stock Options |
| Gwenn Hansen Officer | Jun 25, 2026 | 5,394 | $104.10K | Jun 25, 2026 | Restricted Stock Units |
| Christine Ring Officer | Jun 2, 2026 | 8,148 | $141.69K | Jun 2, 2026 | Restricted Stock Units |
| Johannes Van Houte Officer | May 5, 2026 | 14,055 | $237.95K | May 5, 2026 | Restricted Stock Units |
See a number that looks wrong?